Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Cynthia Aranow, ACR 2021: Subcutaneous Belimumab and Rituximab Sequential Therapy in Systemic Lupus Erythematosus

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 14th 2021

It was a pleasure to speak with Professor Cynthia Aranow (Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA) around the BLISS-BELIEVE study, investigating sequential belimumab and rituximab therapy in SLE (NCT03312907).

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract entitled ‘Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study.’ (ABSTRACT NUMBER: L13) was presented at the ACR Convergence, 5-9 November 2021.

Questions

  1. What are the unmet needs in the treatment of patients with systemic lupus erythematosus (SLE)? (0:25)
  2. What is the rationale for sequential belimumab and rituximab therapy in SLE? (1:31)
  3. What were the aims, design and inclusion criteria of the BLISS-BELIEVE study? (3:31)
  4. What were the efficacy, safety and tolerability findings of the study? (5:29)
  5. Following these findings, what future studies are planned? (6:43)

Disclosures: Cynthia Aranow discloses consulting for GlaxoSmithKline, Kezar Life Sciences, Bristol Myers Squibb and AstraZeneca.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the virtual ACR Convergence 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup